Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)
Cogent Biosciences (COGT) posted quarterly Current Deferred Revenue of $312000.0 for Q2 2020, down 97.95% year-over-year from $15.2 million in Q3 2019, and down 62.9% quarter-over-quarter from $841000.0 in Q1 2020.
Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020) Analysis & Trends
Cogent Biosciences (COGT) has reported Current Deferred Revenue for 4 consecutive years, with $312000.0 the latest figure, recorded in Q2 2020.
- In Q2 2020, Current Deferred Revenue fell 97.95% year-over-year to $312000.0; the TTM figure through Jun 2020 stood at $312000.0 (down 97.95% YoY), while the FY2019 annual figure was $1.3 million, down 92.67% from the prior year.
- Current Deferred Revenue retreated to $312000.0 in Q2 2020 per COGT's latest filing, from $841000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $20.4 million in Q2 2018 and bottomed at $312000.0 in Q2 2020.
- Historically, Current Deferred Revenue has averaged $12.0 million across 4 years, with a median of $15.2 million in 2019.
- Annual changes were most pronounced in 2018 — Current Deferred Revenue soared 160.47% — and 2020, when it slumped 97.95%.
- Cogent Biosciences' Current Deferred Revenue stood at $6.9 million in 2017, then jumped by 160.47% to $17.9 million in 2018, then sank by 92.67% to $1.3 million in 2019, then sank by 76.27% to $312000.0 in 2020.
- Business Quant data shows COGT's Current Deferred Revenue at $312000.0 in Q2 2020, $841000.0 in Q1 2020, and $1.3 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 312,000.00 |
| Mar 31, 2020 | 841,000.00 |
| Dec 31, 2019 | 1.32 Mn |
| Sep 30, 2019 | 14.72 Mn |
| Jun 30, 2019 | 15.20 Mn |
| Mar 31, 2019 | 16.90 Mn |
| Dec 31, 2018 | 17.95 Mn |
| Sep 30, 2018 | 20.10 Mn |
| Jun 30, 2018 | 20.36 Mn |
| Mar 31, 2018 | 17.52 Mn |
| Dec 31, 2017 | 6.89 Mn |